ROLE OF CONTRAST-ENHANCED CT PARANASAL SINUSES IN DIAGNOSING RHINOSINOMUCORMYCOSIS IN POST COVID PATIENTS
DOI:
https://doi.org/10.54112/bcsrj.v2024i1.1448Keywords:
Rhinosinomucormycosis, COVID-19, Contrast-enhanced CT, Paranasal sinuses, Post-COVID complications, PakistanAbstract
Rhinosinomucormycosis is a life-threatening fungal infection that has emerged as a significant complication in post-COVID-19 patients, particularly in those with diabetes or corticosteroid use. Early diagnosis is critical, and contrast-enhanced CT (CECT) has proven valuable in detecting characteristic features of the disease. Objective: This study evaluates the role of CECT in diagnosing rhinosinomucormycosis in post-COVID patients in Pakistan. Methods: A retrospective observational study was conducted at a tertiary care hospital in Rawalpindi from March 2021 to September 2021. Ninety patients with clinical suspicion of rhinosinomucormycosis following COVID-19 were included. All patients underwent CECT of the paranasal sinuses, and imaging findings were correlated with histopathological results. Demographic data, risk factors, and clinical outcomes were also analyzed. Results: The sensitivity of CECT in diagnosing rhinosinomucormycosis was 95%. Common imaging findings included sinonasal mucosal thickening (86.7%), bone erosion (72.2%), intraorbital extension (53.3%), and intracranial extension (23.3%). Diabetes mellitus (71.1%) and corticosteroid use (70%) were the most prevalent risk factors. Patients with intraorbital or intracranial involvement had higher rates of complications, including surgical intervention (63.3%) and mortality (6.7%).Conclusion: Contrast-enhanced CT is a reliable diagnostic tool for rhinosinomucormycosis in post-COVID-19 patients, enabling early detection and management of the disease. Incorporating CECT into routine diagnostic protocols can significantly improve outcomes, particularly in high-risk populations in resource-constrained settings.
Downloads
References
John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis. J Fungi (Basel). 2021;7(4):298.
Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SC, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology. Lancet Infect Dis. 2019;19(12):e405–21.
Basit A, Fawwad A, Qureshi H, Shera AS. Prevalence of diabetes, prediabetes, and associated risk factors: Second National Diabetes Survey of Pakistan (NDSP), 2016-2017. BMJ Open. 2018;8(8):e020961.
Therakathu J, Prabhu S, Irodi A, Sudhakar SV, Yadav VK, Rupa V. Imaging features of rhinocerebral mucormycosis: A study of 43 patients. Eur J Radiol. 2015;84(12):2317–24.
Pakdel F, Ahmadikia K, Salehi MR, Tavakolpour S, Jafari R, Mehrparvar G, et al. Mucormycosis in patients with COVID-19: A systematic review. Mycoses. 2021;64(10):102–9.
Khan M, Akhtar J, Shafiq M, Nasim S. COVID-19-associated mucormycosis in Pakistan: A case series and literature review. J Pak Med Assoc. 2022;72(5):981–5.
Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum. J Laryngol Otol. 2021;135(5):442–7.
Ahmadikia K, Hashemi SJ, Khodavaisy S, Getso MI, Alijani N, Ghasemi Z, et al. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of mucormycosis. J Med Case Rep. 2021;15(1):537.
Malik A, Hussain A, Rana ZA, Jamil B, Arif F. Mucormycosis: The hidden epidemic in diabetic patients in South Asia. BMC Infect Dis. 2021;21(1):776.
Therakathu J, Prabhu S, Irodi A, Sudhakar SV, Yadav VK, Rupa V. Imaging features of rhinocerebral mucormycosis: A study of 43 patients. Eur J Radiol. 2015;84(12):2317–24.
Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum. J Laryngol Otol. 2021;135(5):442–7.
Pakdel F, Ahmadikia K, Salehi MR, Tavakolpour S, Jafari R, Mehrparvar G, et al. Mucormycosis in patients with COVID-19: A systematic review. Mycoses. 2021;64(10):102–9.
John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis. J Fungi (Basel). 2021;7(4):298.
Khan M, Akhtar J, Shafiq M, Nasim S. COVID-19-associated mucormycosis in Pakistan: A case series and literature review. J Pak Med Assoc. 2022;72(5):981–5.
Ahmadikia K, Hashemi SJ, Khodavaisy S, Getso MI, Alijani N, Ghasemi Z, et al. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of mucormycosis. J Med Case Rep. 2021;15(1):537.
Malik A, Hussain A, Rana ZA, Jamil B, Arif F. Mucormycosis: The hidden epidemic in diabetic patients in South Asia. BMC Infect Dis. 2021;21(1):776.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 S MAQSOOD , HH MUGHAL
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.